it 603

(E/Z)-IT-603 is a cell-permeable c-Rel inhibitor (IC50: 3μM) that directly and reversibly binds to c-Rel, altering its conformation and inhibiting its DNA binding and transcriptional activity.

CRBN ligand-603 is an E3 ubiquitin ligase cereblon (CRBN) ligand that functions to recruit cereblon proteins. It can be linked via a linker to a target protein ligand to form a PROTAC.

TAK-603 is an anti-rheumatic drug and is also anti-inflammatory compound. It selectively suppresses Th1 cytokine production and inhibits the progression of adjuvant arthritis.

PSB-603 is a selective antagonist of Adenosine A2B receptor(Ki = 0.553 nM) with anti-inflammatory effects.

NP603 is a highly potent fibroblast growth factor receptor 1 (FGFR1) inhibitor that significantly inhibits rhFGF‑2-induced proliferation of human umbilical vein endothelial cells (HUVECs), with a minimum effective dose of 0.4 μM.

HX-603 is a selectivity agonist of RXR that inhibits the activation of RAR-RXR heterodimers as well as RXR homodimers.

AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].

RL-603, a metabolite of Anagrelide, exhibits platelet-reducing activity in a mouse model.

α-Synucleinmodulator 1 (Compound 7k) acts as a modulator of α-synuclein. In an ACN/PBS (1:1) buffer solution, it exhibits maximum absorption and emission wavelengths at 386 nm and 603 nm, respectively.

TEAD-IN-1 (Compound 2) is an effective inhibitor of TEAD auto-palmitoylation with an IC50 of 603 nM. It enhances the interaction between TEAD and VGLL4, while diminishing the interaction between YAP and TEAD. TEAD-IN-1 is applicable for cancer research.

(Rac)-LRK-4189 is the racemate of LRK-4189. LRK-4189 (Compound 603) is an orally active, selective PIP4K2C PROTAC degrader with a DC50 of less than 500 nM in MOLT-4 cells. It possesses antitumor properties, inducing intrinsic cell death and activating interferon signaling, which leads to immune-mediated tumor killing in immune-inert microsatellite stable (MSS) colorectal cancer (CRC) cells. LRK-4189 is applicable in researching cancers such as MSS colorectal cancer.

GW701427A is a dual inhibitor targeting Fluc and VEGFR2, with IC50 values of 0.12 μM and 603 nM, respectively. It functions as a protein kinase inhibitor on both ATP-dependent and -independent luciferases, potentially affecting Fluc reporter assays [1].

MMV666810 is an antimalarial lead with cross-lifecycle activity. It shows potent killing effects against asexual and gametocyte stages of P. falciparum.